Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsRecruiting
NCT07307235Phase 4Updated Jul 7, 2026
Sponsor: Shanghai Zhongshan Hospital
Type 2 Diabetes
China
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)Completed
NCT03849716N/AUpdated Jul 6, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Canada +4 more
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Terminated
NCT05086315Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Sanofi
Acute Lymphocytic Leukaemia · Acute Myeloid Leukaemia Refractory · Myelodysplastic Syndromes · Blastic Plasmacytoid Dendritic Cell Neoplasia
United States, Australia, China, France, Netherlands
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisRecruiting
NCT07112378Phase 3Updated Jul 6, 2026
Sponsor: Regeneron Pharmaceuticals
Eosinophilic Esophagitis (EoE)
United States
LATE-ONSET POMPE DISEASE AND CEREBROVASCULAR MANIFESTATIONSCompleted
NCT07685314N/AUpdated Jul 6, 2026
Sponsor: Hospitales Universitarios Virgen del Rocío
Late-Onset Pompe Disease
Spain
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)Recruiting
NCT05263206Phase 3Updated Jul 6, 2026
Sponsor: Sanofi
Pruritus
United States, Argentina, Canada, China, France +8 more
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on DialysisTerminated
NCT02859896Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Secondary Hyperparathyroidism-Chronic Kidney Disease
United States, Chile
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)Active Not Recruiting
NCT06687980Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Lichen Simplex Chronicus
United States, Argentina, Belgium, Canada, Chile +12 more
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsEnrolling By Invitation
NCT05492578Phase 2, Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Bulgaria +24 more
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyEnrolling By Invitation
NCT06914908Phase 2Updated Jul 2, 2026
Sponsor: Sanofi
Chronic Rhinosinusitis With Nasal Polyps
United States, Argentina, Belgium, Bulgaria, Poland +1 more
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive Not Recruiting
NCT04850599Phase 2Updated Jul 2, 2026
Sponsor: OHSU Knight Cancer Institute
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorRecruiting
NCT06241118Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Canada +18 more
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)Active Not Recruiting
NCT06687967Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Lichen Simplex Chronicus
United States, Argentina, Canada, Chile, China +12 more
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) RegistryNot Yet Recruiting
NCT07612878N/AUpdated Jul 2, 2026
Sponsor: Sanofi
COPD (Chronic Obstructive Pulmonary Disease)
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple MyelomaCompleted
NCT06203912Phase 1Updated Jul 1, 2026
Sponsor: Elvira Umyarova
Recurrent Multiple Myeloma · Refractory Multiple Myeloma
United States
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesRecruiting
NCT06791291Phase 2Updated Jul 1, 2026
Sponsor: Sanofi
Type 1 Diabetes Mellitus
Japan
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaRecruiting
NCT07225569Phase 2Updated Jul 1, 2026
Sponsor: Sanofi
Hidradenitis Suppurativa
United States, Argentina, Australia, Belgium, Brazil +10 more
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell CarcinomaCompleted
NCT00183820Phase 2Updated Jul 1, 2026
Sponsor: University of Southern California
Testicular Cancer · Germ Cell Neoplasm
United States
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationRecruiting
NCT07215234Phase 1, Phase 2Updated Jul 1, 2026
Sponsor: Sanofi
Geographic Atrophy
United States, Australia
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May HaveActive Not Recruiting
NCT05831176Phase 2Updated Jul 1, 2026
Sponsor: Regeneron Pharmaceuticals
Eosinophilic Gastritis (EoG) · Eosinophilic Duodenitis (EoD) · Eosinophilic Gastrointestinal Disease (EGID) · Eosinophilic Gastroenteritis
United States, Canada, Italy, Japan
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT07184931Phase 3Updated Jul 1, 2026
Sponsor: Sanofi
Crohn's Disease
United States, Argentina, Australia, Austria, Belgium +26 more
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseRecruiting
NCT07190196Phase 3Updated Jul 1, 2026
Sponsor: Sanofi
Immunoglobulin G4 Related Disease
United States, Argentina, Belgium, Canada, Chile +14 more
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaActive Not Recruiting
NCT06676319Phase 2Updated Jul 1, 2026
Sponsor: Sanofi
Asthma
United States, Argentina, Belgium, Brazil, Canada +17 more
Quantifying the Burden of Type 2 (T2) Inflammation in AsthmaNot Yet Recruiting
NCT07675044N/AUpdated Jun 30, 2026
Sponsor: Icahn School of Medicine at Mount Sinai
Asthma · Type 2 Asthma
United States
Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).Available
NCT07675031N/AUpdated Jun 30, 2026
Sponsor: Sanofi
Type 3 Gaucher Disease

Previous page Next page